{"id":6669,"date":"2024-11-21T16:01:35","date_gmt":"2024-11-21T15:01:35","guid":{"rendered":"https:\/\/beigen.vipdev.lndo.site\/us\/?post_type=publication&p=6669"},"modified":"2025-04-28T21:29:27","modified_gmt":"2025-04-28T19:29:27","slug":"tislelizumab-plus-chemotherapy-versus-placebo-plus-chemotherapy-as-first-line-treatment-for-advanced-or-metastatic-oesophageal-squamous-cell-carcinoma-rationale-306-a-global-randomised-placebo-co","status":"publish","type":"publication","link":"https:\/\/beonemedaffairs.com\/us\/publication\/tislelizumab-plus-chemotherapy-versus-placebo-plus-chemotherapy-as-first-line-treatment-for-advanced-or-metastatic-oesophageal-squamous-cell-carcinoma-rationale-306-a-global-randomised-placebo-co\/","title":{"rendered":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study\u00a0"},"content":{"rendered":"","protected":false},"template":"","post-tag":[],"class_list":["post-6669","publication","type-publication","status-publish","hentry","disease_state-esophageal-squamous-cell-carcinoma","molecule-tislelizumab"],"acf":[],"_links":{"self":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication\/6669","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication"}],"about":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/types\/publication"}],"wp:attachment":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/media?parent=6669"}],"wp:term":[{"taxonomy":"post-tag","embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag?post=6669"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}